Illexcor Stake Gets Zydus Once-Daily Candidate For Sickle Cell Disease
Recent Novartis, Pfizer Setbacks
A stake acquisition in US venture Illexcor allows India's Zydus to get in on the ground floor for a potential once-daily sickle cell disease treatment. The candidate showed promising preclinical results in a field that has yielded mixed outcomes for global majors like Novartis, Pfizer and Novo Nordisk
